Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Complementary Medicines
Database
Language
Affiliation country
Publication year range
1.
Chem Pharm Bull (Tokyo) ; 71(5): 374-379, 2023.
Article in English | MEDLINE | ID: mdl-37121688

ABSTRACT

Screening for bioactivity related to anti-infective, anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-viral activity, led us to identify active compounds from a methanol extract of Litsea japonica (Thub.) Juss. and the hot water extract of bark of Cinnamomum sieboldii Meisn (also known as Karaki or Okinawa cinnamon). The two main components in these extracts were identified as the catechin trimers (+)-cinnamtannin B1 and pavetannin B5. Moreover, these extracts exhibited anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) activity. The structures of these catechin trimers were previously determined by chemical and spectroscopic methods. Pavetanin B5 has never been reported to be isolated as a pure form and has been obtained as a mixture with another component. Although other groups have reported the putative structure of pavetannin B5, preparation of the methylated derivative of pavetannin B5 in this study allowed us to obtain the pure form for the first time as the undecamethyl derivative and confirm its exact structure. Commercially available (+)-cinnamtannin B1 and aesculitannin B (C2'-epimer of cinnamtannin B1) both of which contained pavetannin B5 as a minor component, and C. sieboldii bark extract (approx. 5/2 mixture of (+)-cinnamtannin B1/pavetannin B5) were assessed for anti-SARS-CoV-2 activity. Both C. sieboldii bark extract and commercially available aesculitannin B showed viral growth inhibitory activity.


Subject(s)
COVID-19 , Catechin , Cinnamomum , Methicillin-Resistant Staphylococcus aureus , Catechin/pharmacology , Plant Bark/chemistry , SARS-CoV-2 , Plant Extracts/chemistry
2.
Cell Rep ; 35(10): 109218, 2021 06 08.
Article in English | MEDLINE | ID: mdl-34038715

ABSTRACT

Although the main cellular target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is thought to be alveolar cells, the absence of their tractable culture system precludes the development of a clinically relevant SARS-CoV-2 infection model. Here, we establish an efficient human alveolosphere culture method and sphere-based drug testing platform for SARS-CoV-2. Alveolospheres exhibit indolent growth in a Wnt- and R-spondin-dependent manner. Gene expression, immunofluorescence, and electron microscopy analyses reveal the presence of alveolar cells in alveolospheres. Alveolospheres express ACE2 and allow SARS-CoV-2 to propagate nearly 100,000-fold in 3 days of infection. Whereas lopinavir and nelfinavir, protease inhibitors used for the treatment of human immunodeficiency virus (HIV) infection, have a modest anti-viral effect on SARS-CoV-2, remdesivir, a nucleotide prodrug, shows an anti-viral effect at the concentration comparable with the circulating drug level. These results demonstrate the validity of the alveolosphere culture system for the development of therapeutic agents to combat SARS-CoV-2.


Subject(s)
Alveolar Epithelial Cells/drug effects , Antiviral Agents/pharmacology , COVID-19 Drug Treatment , Drug Evaluation, Preclinical , SARS-CoV-2/drug effects , Alveolar Epithelial Cells/metabolism , Alveolar Epithelial Cells/virology , Angiotensin-Converting Enzyme 2/metabolism , COVID-19/metabolism , COVID-19/virology , Cells, Cultured , Host-Pathogen Interactions , Humans , Proto-Oncogene Proteins c-akt/metabolism , SARS-CoV-2/growth & development , SARS-CoV-2/pathogenicity , Spheroids, Cellular , Time Factors , Virus Replication/drug effects , Wnt Signaling Pathway
3.
Biosci Biotechnol Biochem ; 74(3): 541-7, 2010.
Article in English | MEDLINE | ID: mdl-20208365

ABSTRACT

Noroviruses (NoVs), which cannot be grown in cell culture, are a major infectious agent of gastroenteritis. An in vitro assay system was established for the evaluation of NoV binding to enterocytes using virus-like particles (VLPs) produced in a baculovirus system expressing a NoV VP1 capsid protein. After confirmation of the purity by MS analysis, VLPs were incubated with human intestinal Caco-2 cells. NoV VLPs were detected clearly by confocal laser microscopy only on a certain population of Caco-2 cells, and were semi-quantified by immunoblotting of cell lysates. Then the suppressive effect of pasteurized bovine colostrum was analyzed on the VLP binding to Caco-2 cells by immunoblotting. The colostrum reduced VLP binding in a dose-dependent manner, at about 50% suppression with 12.5 microg of the colostral proteins. Furthermore, the colostrum contained IgG antibodies reacting to VLPs, suggesting that cross-reactive antibodies in the bovine colostrums block human NoV binding to intestinal cells.


Subject(s)
Capsid Proteins/immunology , Colostrum/immunology , Gastroenteritis/virology , Norovirus/immunology , Virion/immunology , Virus Attachment , Animals , Antibodies, Viral/immunology , Biological Assay , Caco-2 Cells , Cattle , Female , Humans , Immunoglobulin G/immunology , Pregnancy
SELECTION OF CITATIONS
SEARCH DETAIL